*Disseminated on Behalf of Citius Pharmaceuticals, Inc. Please see disclosures below. |
| Look Into Citius Pharmaceuticals - Here's Why |
| | | | | Hey Folks,
Here are a few reasons to pay attention to Citius Pharmaceuticals, Inc. (CTXR):
1. LYMPHIR is already FDA-approved and commercially launched, with $3.9 million in revenue reported in just the first weeks of sales through a nationwide distributor network. 2. Mino-Lok completed a full Phase 3 trial and achieved both its primary and secondary endpoints with very high statistical significance. 3. If approved, Mino-Lok would be the first and only FDA-approved antibiotic lock solution for salvaging infected catheters — addressing a $2 billion global market. 4. Mino-Lok holds Qualified Infectious Disease Product (QIDP) designation, making it eligible for priority review and a rolling NDA submission to the FDA. 5. Halo-Lido would be the first FDA-approved prescription product to treat hemorrhoids — a condition affecting roughly half of all adults over 50 with zero current prescription competition. 6. Co-founders have invested a combined $26.5 million of their own money into the company, with CEO Leonard Mazur personally putting in $22.5 million.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Citius Pharmaceuticals, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via YouTube, email, and SMS on behalf of Citius Pharmaceuticals, Inc. (CTXR) from March 10, 2026 to March 11, 2026. ZipTrader has been compensated nineteen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) on November 11, 2024. ZipTrader has been compensated seventeen thousand five hundred USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Pharmaceuticals Inc. (CTXR) from August 4, 2024 to August 5, 2024. ZipTrader has been compensated twenty thousand USD by ACH Bank Transfer by Lifewater Media to distribute media for Citius Pharmaceuticals Inc. (CTXR) on January 25, 2023. ZipTrader has been compensated fifteen thousand USD by ACH Bank Transfer by Lifewater Media to distribute media via email and SMS for Citius Oncology Inc. (CTOR) on September 23, 2024. Citius Oncology Inc. (CTOR) is a subsidiary of Citius Pharmaceuticals Inc. (CTXR). ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Citius Pharmaceuticals, Inc. (CTXR). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Citius Pharmaceuticals, Inc. (CTXR). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Citius Pharmaceuticals, Inc. (CTXR), increased trading volume, and possibly an increased share price of Citius Pharmaceuticals, Inc. (CTXR), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
